In July a NY Times article, Progress is seen in an inexpensive cholera vaccine, hailed the progress that’s been made since the 2010 earthquake in Haiti, largely due to the use of OCV. Many of you contributed to the article. All of you have contributed to the progress achieved. The work has reached further and with greater impact than the NYT article described. While there is still insufficient vaccine available, OCV and other interventions, will prove to be useful tools in mitigating the impact of the current humanitarian crises we are witnessing. Our discussion on the priorities and the recommendations we agreed on were summarized in a consensus statement that has been submitted to Vaccine for consideration for publication; it will be posted on the Coalition website. The Secretariat will seek funding from alternative sources to enable continuation of the Coalition.
In September we agreed that there is much that has yet to accomplished. Among the most pressing issues are vaccine shortage, advocacy and resource mobilization. The OCV stockpile has been established and Gavi has committed to support it over a 5 year period. Unfortunately, OCV production has not increased to match the demand and so far this year requests from 5 countries totaling ~1.5 million doses have been rejected due to unavailability. We are in communication with WHO, Gavi, and Sanofi to see if there is anything we can do to increase availability of Shanchol.